RxDoctor Payments DataLook up a doctor →

Susan Anderson

Nurse Practitioner · Gallatin, TNNPI 1891726709

Payments from drug & device makers

$23,731in general payments, 2019–2025

Across 618 payments — averaging $38.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13K
  • Lilly USA, LLC$4K
  • Novo Nordisk$1K
  • Amgen$763
  • Takeda Pharmaceuticals U.S.A., Inc.$571
  • Astellas Pharma US Inc$344
  • plus $3K from 37 others

What the payments were for

  • Consulting fees$2,50011%
  • Speaking & faculty fees$11,91950%
  • Travel & lodging$4502%
  • Food & beverage$8,56236%
  • Education$3011%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,731 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$49,631
Medicare patients
181
Services billed
1,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide90$103,139
OzempicSemaglutide37$45,521
Soliqua 100-33Insulin Glargine/Lixisenatide39$42,933
JardianceEmpagliflozin21$28,488
EliquisApixaban21$26,721
FarxigaDapagliflozin Propanediol14$19,873
Tresiba Flextouch U-200Insulin Degludec17$18,173
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$13,257
TradjentaLinagliptin13$12,354
LinzessLinaclotide13$11,719
Dexlansoprazole DrDexlansoprazole19$6,149
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,106
SynthroidLevothyroxine Sodium42$4,033
Varenicline Tartrate11$3,952
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$4,273$103,13990 claims
Novo NordiskOzempic$1,057$45,52137 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$213$42,93339 claims
Boehringer IngelheimJardiance, Tradjenta$37$40,84234 claims
PfizerEliquis$211$26,72121 claims
AstraZenecaFarxiga$113$19,87314 claims
GSKAnoro Ellipta, Shingrix$64$17,36334 claims
AbbVieLinzess, Synthroid$13,244$15,75255 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Gallatin

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →